Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on March 21, 2024, covering an event reported on March 20, 2024. The Company is a Delaware corporation headquartered in Nashville, Tennessee, focused on ophthalmic products, specifically its product IHEEZO.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory event rather than periodic financial results.
Material Changes and Events
On March 20, 2024, the Company received confirmation from the Centers for Medicare & Medicaid Services (CMS) regarding a request made in February 2024. CMS decided to increase the Medically Unlikely Edits (MUE) for IHEEZO's J-Code (J-2403) from 1 to 2. This change addresses the limitation where only a single vial could be billed, whereas bilateral ocular procedures often require two vials.
Outlook, Management Commentary, and Risks
According to the communication from the National Correct Coding Initiative (NCCI) program of CMS:
- The MUE edit increase is expected to be effective in July 2024.
- The change will be made retroactive for procedures dating back to January 1, 2024.
- The Company notes that while the decision has been communicated, it is not final until officially published.
Key Facts for Investor Verification
- Verify the official publication date of the CMS MUE edit change to confirm the July 2024 effective date.
- Monitor the Company's future financial reports for the impact of retroactive billing adjustments for procedures performed between January 1, 2024, and the effective date.
- Assess the potential revenue uplift from enabling bilateral billing for IHEEZO in the Medicare population.